A dose-response study of I3-cis-retinoic acid in acne vulgaris.
13-cis-retinoic acid has been used as a single agent in the treatment of seventy-six patients with previously unresponsive cystonodular acne. The study was carried out in a double-blind fashion using three doses of the drug. Ninety per cent of the patients responded with a 70% improvement in the acne severity. Sixty-six per cent of the patients experienced no further problems with their acne during follow-up. Side-effects were frequent. The 0.5 mg/kg b.w. dose is recommended for the initial course of treatment.
D000152:Acne Vulgaris / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015474:Isotretinoin; D008055:Lipids / Q000097:blood; D008297:Male; D012629:Sebum / Q000378:metabolism; D013997:Time Factors; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D008055:Lipids; D014212:Tretinoin; D001219:Aspartate Aminotransferases; D015474:Isotretinoin